| (1) |
Cancer facts and figures, 1995. New York: American Cancer
Society, 1995. |
| (2) |
NCI releases results of nationwide study of radioactive
fallout from nuclear tests. Press release of the National Cancer Institute,
Bethesda, Md., August 1, 1997. (http://rex.nci.nih.gov/). |
| (3) |
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant
CS. Predicting outcome in papillary thyroid carcinoma: development of a
reliable prognostic scoring system in a cohort of 1779 patients surgically
treated at one institution during 1940 through 1989. Surgery 1993; 114:
1050-8. |
| (4) |
Mazzaferri EM, Jhiang SM. Long-term impact of initial
surgical and medical therapy on papillary and follicular thyroid cancer.
Am J Med 1994; 97: 418-28. [Erratum, Am J Med 1995; 98: 215.] |
| (5) |
Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic
factors for thyroid carcinoma: a population-based study of 15,698 cases
from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.
Cancer 1997; 79: 564-73. |
| (6) |
Mazzaferri EL. Thyroid remnant 131I ablation for papillary
and follicular thyroid carcinoma. Thyroid 1997; 7: 265-71. |
| (7) |
Johansen K, Woodhouse NJ, Odugbesan O. Comparison of
1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid
tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;
32: 252-4. |
| (8) |
Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy
F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated
differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105. |
| (9) |
Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison
of administration of recombinant human thyrotropin with withdrawal of thyroid
hormone for radioactive iodine scanning in patients with thyroid carcinoma.
N Engl J Med 1997; 337: 888-96. |
| (10) |
Pujol P, Daures J-P, Nsakala N, Baldet L, Bringer J,
Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant
in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318-23. |